Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2017, Article ID 5183646, 4 pages
https://doi.org/10.1155/2017/5183646
Case Report

Utility of MYD88 in the Differential Diagnosis and Choice of Second-Line Therapy in a Case of Nonsecretory Lymphoplasmacytic Lymphoma versus Free Light Chain Waldenstrom’s Macroglobulinemia

1Geisinger Commonwealth School of Medicine, 521 Pine Street, Scranton, PA 18510, USA
2Division of Hematology and Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
3Hematology & Oncology Associates of Northeastern Pennsylvania, 1100 Meade Street, Dunmore, PA 18512, USA

Correspondence should be addressed to C. Barsigian; moc.nsm@naigisc

Received 15 September 2016; Revised 20 December 2016; Accepted 9 January 2017; Published 12 February 2017

Academic Editor: Uma Dasgupta

Copyright © 2017 D. Kazmierski et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

D. Kazmierski, M. L. Palomba, and C. Barsigian, “Utility of MYD88 in the Differential Diagnosis and Choice of Second-Line Therapy in a Case of Nonsecretory Lymphoplasmacytic Lymphoma versus Free Light Chain Waldenstrom’s Macroglobulinemia,” Case Reports in Hematology, vol. 2017, Article ID 5183646, 4 pages, 2017. https://doi.org/10.1155/2017/5183646.